This early study tests whether adding an experimental drug called SION-719 to the standard CF medicine Trikafta is safe and tolerable. Sixteen adults with cystic fibrosis who have two copies of the F508del mutation will receive either SION-719 or a placebo alongside their usual T…
Phase: PHASE2 • Sponsor: Sionna Therapeutics Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC